摘要
目的:探讨"三阴性"乳腺癌Ki-67表达对新辅助化疗疗效的预测价值,有助于乳腺癌治疗的选择及预后。方法:对74例分别实施TEC及CEF方案新辅助化疗的"三阴性"乳腺癌病例进行回顾性分析,应用免疫组化法检测化疗前后Ki-67表达,分析Ki-67表达与疗效关系。结果:Ki-67高表达患者接受CET新辅助化疗化疗PCR率更高。结论:Ki-67的高表达可以作为"三阴性"乳腺癌CET方案化疗疗效预测指标。
Objective： To explore the influence of Ki-67 expression in triple-negative breast cancer to the predictive value of neo-adjuvant chemotherapy, and to assist selecting of treatment methods and progno- sis of breast cancer. Methods： Retrospective analysis was carried out in 74 patients with triple- negative breast cancer who underwent TEC and CEF neo-adjuvant chemotherapy regimens, and the expression of Ki- 67 was investigated by immunohistochemistry. In addition, the relation between Ki-67 expression and treat- ment effect was also analyzed. Result： PCR rate was detected high in patients with high Ki-67. expression. Conclusions：High Ki-67 expression can be regarded as the predictive index of CEF chemotherapy regimen in triple-negative breast cancer.
出处
《河北医学》
CAS
2013年第6期832-834,共3页
Hebei Medicine
关键词
乳腺癌
新辅助化疗
KI-67
Breast cancer
Neo-adjuvant Chemotherapy
Ki-67
